Comparing two treatments for relapsed or resistant AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding venetoclax to a standard chemotherapy regimen (CLAG) works better than the chemotherapy alone for adults whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have acute myeloid leukemia (AML) that has returned after treatment or has not responded to treatment.
- You are able to take oral venetoclax.
- You have adequate kidney and liver function.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding venetoclax (a targeted drug) to standard chemotherapy helps patients with acute myeloid leukemia (a blood cancer) who have responded well to initial treatment stay cancer-free longer. You would receive the combination or standard therapy alone to see which works better.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Hear when a new Relapsed/Refractory AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.